Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Peritoneal Dialysis
Conditions
Peritoneal Dialysis, Chronic Kidney Disease
Trial Timeline
Dec 1, 2004 → Apr 1, 2006
NCT ID
NCT00196755About Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )
Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® ) is a phase 3 stage product being developed by Sanofi for Peritoneal Dialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT00196755. Target conditions include Peritoneal Dialysis, Chronic Kidney Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00196755 | Phase 3 | Completed |
Competing Products
20 competing products in Peritoneal Dialysis